Women with CHD more likely to have safe and healthy pregnancies, study finds

Congenital heart disease (CHD), a group of abnormalities in the heart that develop before birth - including holes in the heart, leaky or narrow valves, and incomplete or missing parts - affects nearly one percent of all babies born in the United States each year - upwards of 40,000 infants. Early in their lives these children often undergo multiple cardiovascular surgeries to repair their hearts, and have to be cared for by a cardiologist for the rest of their lives. In recent years treatments for these defects have saved the lives of thousands of children who once died in childhood. As more women with CHD survive into their childbearing years, new challenges have arisen: doctors must now assess their risk for pregnancy-related complications and care for those issues throughout the pregnancy.

New research from the Perelman School of Medicine at the University of Pennsylvania reveals that women with CHD who are deemed high risk by conventional measures are more likely to have safe, healthy pregnancies than current risk-assessments suggest. Their findings will be presented at the American Heart Association Scientific Sessions 2016.

"Our findings are extremely promising for women with CHD who are entering their childrearing years, as we now know there is a better chance of a healthy, low-risk pregnancy," said the study's lead author, Yuli Kim, MD, director of the Philadelphia Adult Congenital Heart Center, a joint program between Penn Medicine and The Children's Hospital of Philadelphia, and an assistant professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. "With the tools currently used to evaluate risk, such as Pregnancy and Congenital Heart Disease (ZAHARA) and Cardiac Disease in Pregnancy (CARPREG) risk scores, clinicians have actually been over estimating the risk of complication for some of these women, which could be discouraging when making the decision to have children."

The researchers examined 186 women over 18 with CHD who had given birth between 1998 and 2014, and applied risk scores from CARPREG and ZAHARA, and assigned modified WHO criteria to each patient. Cardiac events, such as arrhythmia, heart failure, stroke, heart attack, cardiac arrest, or cardiac death, were assessed for up to six months after birth. There were 31 cardiac events - representing 17 percent of all pregnancies - but none of the women died. With the CARPREG model, the estimated risk versus observed adverse events differed greatly from 75 to 25 percent, and with ZAHARA, estimated risk was 70 percent and observed events were 38 percent.

The CARPREG study, a large prospective study across 13 centers in Canada, evaluated 599 pregnancies that ended in a live birth, to determine and validate a risk score. One point was given to each of the five identified risk factors - including prior episodes of heart failure, stroke before pregnancy, or arrhythmias - and a cardiac event rate was calculated according to the total number accumulated. The other tool currently used, ZAHARA, comes from multicenter registry in the Netherlands and Belgium, which examined 1302 pregnancies in 714 women, which also ended in live birth. Eight risk factors were identified to predict cardiac complications during pregnancy, and ZAHARA assigned points from zero to 13 to each factor with a higher total equating to a higher risk of cardiac complication. Conversely, the modified WHO criteria assigned a risk score to the patient from one to four, based on the mother's level of underlying CHD, history of repair and clinical status.

"Risk assessment tools are very beneficial on a global scale, but the best way to evaluate patients and determine potential risk is to evaluate each patient on an individual level," Kim said. "The results from this study will certainly be helpful in reassuring woman with CHD that most patients in similar situations have successful pregnancy, especially if they are managed in a high-risk clinic."

She noted that additional research is needed in order to better identify higher risk patients, but that this data will be helpful in the clinical management of CHD patients who are navigating their pregnancy, allowing these women to follow a more standard care plan with their cardiologist and OB/GYN.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring Japanese medicine: Longevity, lifestyle, and emerging health priorities